Navigation Links
Orchid Cellmark Reports Third Quarter 2008 Financial Results
Date:11/18/2008

ember 30, 2008 and 2007 (In thousands, except per share data) (Unaudited) Three months ended Nine months ended September 30, September 30, 2008 2007 2008 2007 Revenues: Service revenues $14,845 $15,511 $44,404 $45,100 Other revenues 27 47 219 222 Total revenues 14,872 15,558 44,623 45,322 Operating expenses: Cost of service revenues 10,500 10,054 31,159 29,779 Research and development 228 264 654 832 Marketing and sales 1,536 1,503 4,659 4,500 General and administrative 3,588 3,831 12,639 11,747 Restructuring - (75) - (75) Amortization of intangible assets 475 447 1,429 1,337 Total operating expenses 16,327 16,024 50,540 48,120 Operating loss (1,455) (466) (5,917) (2,798) Other income, net 128 301 846 817 Loss before income tax expense (1,327) (165) (5,071) (1,981) Income tax expense (benefit) 132 542 (117) 1,154 Net loss $(1,459) $(707) $(4,954) $(3,135) Basic and diluted net loss per share $(0.05) $(0.02) $(0.17) $(0.11) Shares used in computing basic and diluted net loss per share: 29,935 29,327 29,935 29,323 Orchid Cellmark Inc. and Subsidiaries Condensed Consolidated Balance Sheets September 30, 2008 and December 31, 2007
'/>"/>
SOURCE Orchid Cellmark Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology news :

1. Saving the wild orchids of Borneo
2. Orchid Cellmark to Present at the 2008 Bank of America Health Care Conference
3. First orchid fossil puts showy blooms at some 80 million years old
4. Communication Intelligence Corporation Reports Third Quarter 2008 Financial Results
5. Synaptics Reports Record Results for First Quarter of Fiscal 2009
6. GEN reports on novel tools for deciphering biological networks
7. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
8. LSUHSC research reports new method to protect brain cells from diseases like Alzheimers
9. Communication Intelligence Corporation Reports Second Quarter 2008 Financial Results
10. BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008
11. BIO-key(R) Reports Profitability on Strong Revenue Growth for Second Quarter 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2009)...ity of North Carolina at Chapel Hill School of Med...sco have developed and experimentally tested a tec... drugs. , The researchers developed a computatio...s of all known drugs are to the naturally occurrin...se targets within the cell. In a study published t...
(Date:11/3/2009)...ore than 25 years, all attempts at culturing pearl...n unsuccessfuluntil now. For the first time, novel...ded (nucleated) and non-beaded cultured pearls fro...s from Florida Atlantic University,s Harbor Branch...o years of research and experimentation, Drs. Hcto...
(Date:11/3/2009)...as 28 percent less likely to become pregnant and h...that earned a Michigan State University professor ..., a researcher in the MSU College of Human Medicin...ductive Biology, focused on data of nearly 50,000 ...Luke,s findings, which also can be applied to wome...
Breaking Biology News(10 mins):Study points to new uses, unexpected side effects of already existing drugs 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 3MSU researcher: Obesity significantly cuts odds of successful pregnancy 2Lexicon Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 55970 1Lexicon Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference 55970 2Added Investment Into Healthcare By the Government Drives Growth in the European Hospital Information Systems Market Notes Frost 26 Sullivan 55968 1Added Investment Into Healthcare By the Government Drives Growth in the European Hospital Information Systems Market Notes Frost 26 Sullivan 55968 2Added Investment Into Healthcare By the Government Drives Growth in the European Hospital Information Systems Market Notes Frost 26 Sullivan 55968 3TrueFACS Announces the Addition of Nora Johnson and Pat Palmer of Medical Billing Advocates of America 55966 1TrueFACS Announces the Addition of Nora Johnson and Pat Palmer of Medical Billing Advocates of America 55966 2
...discovered that human embryonic stem cell lines ac...me. , The findings do not limit the utility of th...ure clinical applications, the researchers say, bu...em cell lines for genetic changes and to study how... researchers, work is described in the Sept. 4 onl...
...s in India has risen in response to a 20-fold drop...ording to an article in the Nov. 15 issue of Clini... introduction of generic drugs into the country ha...of the cheaper cost, the article states. , Many of...g in India have been unable to obtain treatment du...
... people with compromised immune systems may be fea...s, who demonstrated their approach could protect a...same population of immune cells that HIV destroys ...ren,s Hospital of Pittsburgh researchers, working ...ity of Pittsburgh and Louisiana State University, ...
Other Biology News:Embryonic stem cells accrue genetic changes 2Embryonic stem cells accrue genetic changes 3Embryonic stem cells accrue genetic changes 4HIV mortality in India drops with introduction of generic antiretroviral therapy 2New vaccine platform may fight infections with causes from influenza to bioterrorism 2New vaccine platform may fight infections with causes from influenza to bioterrorism 3
(Date:11/7/2009)...,, CAMBRIDGE, Mass., Nov. 7, Re...ochemistry scored top marks this evening, as Tim K...Song and Quan (Jack) Chen of Audubon, PA received ...e 2009 Siemens Competition in Math, Science & ...ce competition. ,, ( http://www.newscom.com/cg...
(Date:11/6/2009)...,, QUINCY, Mass., Nov. 6 Myrian...biotech developer and manufacturer of renewable b...preferred technology provider Uhde GmbH, one of th... "Uhde"), announced an alliance for the engineerin...,s biobased Succinic Acid plants based on renewabl...
(Date:11/6/2009)...,, CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Onc...lytics" or the "Company") today announced updated ...SIN(R) in patients with sarcomas metastatic to the...Connective Tissue Oncology Society Meeting held in...he poster presentation, entitled "A Phase II Study...
(Date:11/5/2009)...,, GAITHERSBURG, Md., Nov. 5 /PRNewswire-FirstC...ced its financial results for the third quarter en... of $3.6 million ($0.04 per share) for the three m...oss of $6.8 million ($0.08 per share) in the compa...eptember 30, 2009, GenVec,s net loss was $14.1 mil...
Breaking Biology Technology:Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 2Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 3Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 4Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 5Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 6Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 2Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 3Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6
... 17 Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ..., today announced that its lead product candidate,...uct designation for the treatment of,small cell lu...designation,is based on a recommendation from the ...the European Medicines Agency (EMEA). Picoplatin ...
...lt announced today that,the Henry C. Witelson Ocul...ealth Centre has purchased a Personal Archive bios... in Montreal, Quebec. GenVault technology will be... in determining the mechanisms underlying eye canc...for developing new approaches for,treatment. These...
...ea Pharmaceuticals,Inc. announced today that BC De...diagnostic test, is now available from Panacea Lab...at should facilitate the identification,of recurre...ncer. Panacea,Laboratories, a division of Panacea ...aboratory Improvement Amendments of 1988 (CLIA). T...
Other Biology Technology:Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer 2Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer 3Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer 4McGill University Purchases GenVault's Personal Archive System to Manage Rare Cancer Samples 2Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer 2Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer 3Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer 4
Recombinant Expression of Peptides and Proteins: from rPeptide, LLC
Polypropylene microtube rotor, 24 1.5 ml + 24 0.5 ml from Thermo Scientific
Wellpro 384 from Thermo Scientific
...er consumption of reagents and increased throughpu...ltidrop 384 is an automated dispenser designed for...ing into 384- and 96-well plates.This new-generati...n easily switch from 96- to 384- well plates and d...
Biology Products: